BIO, PhRMA Urge Delay In Part B Drug Price Substitution Policy Until AMP Reg Finalized
This article was originally published in The Pink Sheet Daily
Executive Summary
BIO and PhRMA urge CMS to delay making reimbursement rate substitutions for Medicare Part B drugs based on comparing ASP to AMP until the agency finalizes its rules on the methodology for calculating AMP. The final AMP rule is expected in 2013.